Angiogenesis
Research Areas
Products Related to Angiogenesis(378)
- GC36821OSU-T315CAS: 2070015-22-2Purity: >98.00%
OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain). OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner. OSU-T315 causes cell death through apoptosis and autophagy.
- GC37672Spebrutinib besylateCAS: 1360053-81-1Purity: >98%
Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a potent inhibitor of Btk kinase activity (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s) in biochemical assays.
- GC37770TFLLR-NH2(TFA)CAS: 1313730-19-6Purity: >99.50%
TFLLR-NH2 (TFA) is a selective PAR1 agonist with an EC50 of 1.9 μM.
- GC37852UDM-001651CAS: 1477497-01-0Purity: >98%
UDM-001651 is a potent, selective, and orally bioavailable protease-activated receptor 4 (PAR4) antagonist (IC50=4 nM; Kd=1.4 nM).
- GC37960ZaurategrastCAS: 455264-31-0Purity: >98.00%
Zaurategrast (CT7758) is a potent and oral-effective α4-integrin inhibitor.
- GC37961Zaurategrast ethyl esterCAS: 455264-30-9Purity: >99.00%
Zaurategrast ethyl ester (CDP323), the ethyl ester prodrug of CT7758, is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders.
- GC37962Zaurategrast ethyl ester sulfateCAS: 1214261-78-5Purity: >98%
Zaurategrast ethyl ester sulfate (CDP323 sulfate), the ethyl ester prodrug of CT7758, is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders.
- GC37966ZINC13466751CAS: 117953-17-0Purity: >98.50%
ZINC13466751 is a potent inhibitor of HIF-1α/von Hippel-Lindau interaction with an IC50 of 2.0 ?M.
- GC37975α2β1 Integrin Ligand PeptideCAS: 134580-64-6Purity: >98%
α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells.
- GC38134Parmodulin 2CAS: 423735-93-7Purity: >98%
Reversible inhibitor of PAR1mediated platelet activation
- GC38329GB-110 hydrochloridePurity: >99.50%
GB-110 hydrochloride is a potent, orally active, and nonpeptidic protease activated receptor 2 (PAR2) agonist.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC36500 | LXW7 | 1313004-77-1 | >98% | |
LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. | ||||
| GC36661 | MT-802 | 2231744-29-7 | >98.50% | |
MT-802 is a potent BTK degrader based on Cereblon ligand, with a DC50 of 1 nM. | ||||
| GC36821 | OSU-T315 | 2070015-22-2 | >98.00% | |
OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain). OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner. OSU-T315 causes cell death through apoptosis and autophagy. | ||||
| GC36861 | PCI 29732 | 330786-25-9 | >99.50% | |
A multi-kinase inhibitor | ||||
| GC37034 | PT2977 | 1672668-24-4 | >98.00% | |
PT2977 is an orally active and selective HIF-2α inhibitor with an IC 50 of 9nM. | ||||
| GC37048 | QL47 | 1469988-75-7 | >98.50% | |
QL47, a broad-spectrum antiviral agent, inhibits dengue virus and other RNA viruses. | ||||
| GC37066 | Rac-PT2399 | 1672662-07-5 | >99.00% | |
A potent and specific HIF-2α inhibitor | ||||
| GC37524 | RGD peptide (GRGDNP) TFA | 114681-65-1 | >98.00% | |
| GC37541 | Risuteganib | 1307293-62-4 | >98% | |
| GC37672 | Spebrutinib besylate | 1360053-81-1 | >98% | |
Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a potent inhibitor of Btk kinase activity (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s) in biochemical assays. | ||||
| GC37770 | TFLLR-NH2(TFA) | 1313730-19-6 | >99.50% | |
TFLLR-NH2 (TFA) is a selective PAR1 agonist with an EC50 of 1.9 μM. | ||||
| GC37801 | TM6089 | 863421-32-3 | >98% | |
TM6089 is a unique Prolyl Hydroxylase (PHD) inhibitor which stimulates HIF activity without iron chelation and induces angiogenesis and exerts organ protection against ischemia. | ||||
| GC37818 | TR-14035 | 232271-19-1 | >99.00% | |
TR-14035 is a orally active dual α4β7/α4β1 integrin antagonist, with IC50 s of 7 nM and 87 nM for α4β7 and α4β1, respectively. | ||||
| GC37852 | UDM-001651 | 1477497-01-0 | >98% | |
UDM-001651 is a potent, selective, and orally bioavailable protease-activated receptor 4 (PAR4) antagonist (IC50=4 nM; Kd=1.4 nM). | ||||
| GC37889 | VCE-004.8 | 1818428-24-8 | >98.00% | |
VCE-004.8 (VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist. | ||||
| GC37960 | Zaurategrast | 455264-31-0 | >98.00% | |
Zaurategrast (CT7758) is a potent and oral-effective α4-integrin inhibitor. | ||||
| GC37961 | Zaurategrast ethyl ester | 455264-30-9 | >99.00% | |
Zaurategrast ethyl ester (CDP323), the ethyl ester prodrug of CT7758, is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders. | ||||
| GC37962 | Zaurategrast ethyl ester sulfate | 1214261-78-5 | >98% | |
Zaurategrast ethyl ester sulfate (CDP323 sulfate), the ethyl ester prodrug of CT7758, is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders. | ||||
| GC37966 | ZINC13466751 | 117953-17-0 | >98.50% | |
ZINC13466751 is a potent inhibitor of HIF-1α/von Hippel-Lindau interaction with an IC50 of 2.0 ?M. | ||||
| GC37975 | α2β1 Integrin Ligand Peptide | 134580-64-6 | >98% | |
α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. | ||||
| GC38044 | Fraxinellone | 28808-62-0 | >99.50% | |
| GC38128 | c(phg-isoD-G-R-(NMe)k) TFA | - | >98% | |
| GC38134 | Parmodulin 2 | 423735-93-7 | >98% | |
Reversible inhibitor of PAR1mediated platelet activation | ||||
| GC38329 | GB-110 hydrochloride | - | >99.50% | |
GB-110 hydrochloride is a potent, orally active, and nonpeptidic protease activated receptor 2 (PAR2) agonist. | ||||